Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Treatment
Researchers from Japan, the United States and Germany describe findings in cancer treatment studies
May 10th, 2006
Cancer treatment research advances have been reported from Japan, the United States and Germany. Study 1: Investigators have identified a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by a herpes simplex virus cancer vaccine. "Despite several ongoing clinical trials of immunotherapies against glioma, few glioma-specific antigens recognized by cytotoxic T lymphocytes (CTLs) have been identified. We recently demonstrated that intratumoral inoculation with herpes simplex virus (HSV) as a cancer vaccine activates tumor-specific CTLs. To identify glioma antigens recognized by CTLs, we used the HSV cancer vaccine to vaccinate mice harboring...
Source: Vaccine Weekly (2006-05-10)
|
